A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector

South African Family Practice

Field Value
Title A description of sodium valproate, lamotrigine and levetiracetam consumption in the Western Cape public sector
Creator Keuler, Nicole Johnson, Yasmina Coetzee, Renier
Subject Family medicine; primary health care; primary care sodium valproate; levetiracetam; lamotrigine; consumption; epilepsy
Description Background: The rational use of medicine is fundamental to ensure effective and safe patient medicine treatment, and hence, should be monitored. Undisputable evidence exists for the teratogenic risk factors associated with sodium valproate. Consequently, the Western Cape Department of Health introduced a policy (2019) recommending alternatives for valproate in women of childbearing age, including lamotrigine or levetiracetam as alternatives for patients on antiretrovirals. This study aimed to describe the change in the consumption of valproate, lamotrigine and levetiracetam after a policy implementation in public sector health facilities of the Western Cape, South Africa.Methods: This observational study followed a quasi-experimental design. Consumption data from the Cape Medical Depot over the period 01 April 2018 to 31 March 2020 were analysed retrospectively. Consumption was presented as a defined daily dose (DDD) per 1000 population per quarter for sodium valproate, levetiracetam and lamotrigine for the Western Cape province, urban and rural areas. Consumption 12 months before was compared with consumption 12 months after policy implementation.Results: Post-policy implementation, valproate consumption remained unchanged provincially (3.3%; p = 0.255), in urban (7.8%; p = 0.255) and rural (1.5%; p = 0.701) areas. Lamotrigine consumption increased significantly provincially (30.7%; p = 0.020) and in urban areas (54.5%; p = 0.002); however, rural (26.1%; p = 0.108) areas did not show significant change. Provincially, valproate consumption remained substantially higher (209 DDDs/1000 population per quarter) compared with lamotrigine consumption (32.22 DDDs/1000 population per quarter).Conclusion: In the Western Cape public sector, the consumption of sodium valproate remained unchanged 12 months after policy implementation. Although there were significant increases in lamotrigine and levetiracetam consumption, the consumption was considerably less compared with sodium valproate consumption. 
Publisher AOSIS
Contributor Petri Steyn, Pharmacy Services, Western Cape
Date 2022-06-02
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed Article Observational study, comparative analysis
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/safp.v64i1.5402
Source South African Family Practice; Vol 64, No 1 (2022): Part 3; 7 pages 2078-6204 2078-6190
Language eng
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://safpj.co.za/index.php/safpj/article/view/5402/7384 https://safpj.co.za/index.php/safpj/article/view/5402/7385 https://safpj.co.za/index.php/safpj/article/view/5402/7386 https://safpj.co.za/index.php/safpj/article/view/5402/7387
Coverage Western Cape; South Africa April 2018 - March 2020 Consumption data
Rights Copyright (c) 2022 Nicole Keuler, Yasmina Johnson, Renier Coetzee https://creativecommons.org/licenses/by/4.0